CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.
- Abstract views: 988
- PDF: 620
- HTML: 15
Copyright (c) 2019 Amrallah A. Mohammed, Hanaa Rashied, Fifi Mostafa Elsayed
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.